Member Posts > Cardiol Therapeutics: Advancing Late-Stage Clinical Trials for Cardiovascular Disease
With a strong clinical pipeline and expanding late-stage trials, Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) is rapidly advancing CardiolRx™ toward regulatory approval. The company's presence at major investor and industry events highlights its commitment to scientific rigor and trial execution.
Upcoming Clinical Development Conferences
📅 TD Cowen 45th Annual Health Care Conference (March 3-5, 2025)
• Discussions on progressing into late-stage trials and regulatory submission plans.
📅 37th Annual ROTH Conference (March 16-18, 2025)
• Focus on scaling up manufacturing and commercialization strategies.
Clinical Trial Updates & Key Findings
🔬 AHA Scientific Sessions 2024 (Nov 18, 2024)
• Presentation of MAvERIC Phase II trial findings supporting further development.
📢 Follow Cardiol's clinical progress:

#Biotech #Investing #StockMarket #CardiolTherapeutics #NASDAQ #Healthcare #Pharma #Finance #MarketNews #HeartHealth #MedicalInnovation #Myocarditis #Pericarditis #HealthcareResearch #CannabidiolResearch #CardiolRx #LifeSciences #BiotechConference #InvestorUpdates